Jump to page content

Project Responsible PrecliniX (RPX)

Translation aims to transform biomedical innovations into clinical practice. This process is challenging and requires the integration of expertise from various disciplines. To foster robust preclinical evidence generation, Responsible PrecliniX (RPX) was recently established as a research and counsel unit at the BIH QUEST Center for Responsible Research. It aims to strengthen the reliability and validity of preclinical findings to increase the probability of translational success. It is complementing the network between clinical study center, regulatory advisors, and core facilities to form a unique structure at a translational research institute. Close collaboration and establishment of communication processes between the network partners will ensure clinical relevance, fit for purpose applications, high-quality standards, and iterative translation i.e., from bench to bed and back.

More information about the PRX.

RPX Kick - Off Event

This meeting should shed light on what Responsible PrecliniX does, how we operate and highlight and establish collaboration(s), handshake processes, and the integration of this unit into the existing ecosystem in translational research at BIH at Charité. Importantly, we will also highlight HOW and WHEN to approach us, our areas of expertise and how we can connect you with partners that complement your expertise.

Content -Together Towards Robust Evidence Generation

Presentations will include:

  • The development and evaluation of a metric to assess internal, external, and translational validity and reliability aspects of projects
  • Workflow for processes - what can we cover, where can we connect you with field-specific experts - “Joint Approaches towards Responsible Translation" 
  • The role of core facilities and their counseling process
  • Regulatory affairs in preclinical research - when, what, how?
  • Patient engagement in preclinical studies

Target Group

Everybody from Charité is welcome. The meeting is particularly targeted at all relevant stakeholders at BIH, that are part of the BIH strategy, like the core facilities and the Clinical study center, as well as funding streams like SPARK and the clinician scientist program. In addition, it targets research groups and individual scientists at BIH/ Charité that aim at translating their preclinical evidence into clinical context.


Date: 4th October 2022, 4 - 6 pm

Followed by a small reception and networking event.

Format: Hybrid - everybody can attend online, there is limited space (up to 20 people) onsite.

The decision for your onsite participation will be made on a first come first serve basis. If you register early and can attend in person you have the opportunity to join us for further networking activities after the event including food and drinks.

Onsite location: Conference room Atrium, Berlin Institute of Health @ Charité, Anna-Louisa-Karsch-Str. 2, 10178 Berlin

Please register here.

Time Topic Who
16:00 - 16:05 Welcome ‘why we are here?’ and introduction ‘what to expect?’ Ulf Tölch
16:05 - 16:20 Presentation RPX “Together towards robust evidence generation” Natascha Drude
16:20 - 16:50 Key Note Patient engagement in preclinical studies Anna Smith
16:50 - 17:00 Open questions, discussion  
17:00 – 17:15 Coffee Break  
17:15 - 17:30 Presentation Core facilities Christian Hirsch, Jennifer Kirwan, Alexandra Stege
17:30 - 17:45 Regulatory consideration in preclinical studies Christoph Conrad
17:45 - 17:55 Q & A  
17:55 - 18:00 Closing remarks Natascha Drude
18:00 - 20:00 Get-together & Networking  
[Translate to englisch:]

Dr. Natascha Drude

Research fellow - Responsible PrecliniX

Contact information
Phone:+49 30 450 543 454